ABSTRACT
Contrafreeloading is the willingness of animals to work for food when equivalent food is freely available. This behavior is observed in laboratory, domesticated, and captive animals. However, previous research found that six laboratory cats failed to contrafreeload. We hypothesized that cats would contrafreeload in the home environment when given a choice between a food puzzle and a tray of similar size and shape. We also hypothesized that more active cats would be more likely to contrafreeload. We assessed the behavior of 17 neutered, indoor domestic cats (Felis catus) when presented with both a food puzzle and a tray across ten 30-min trials. Each cat wore an activity tracker, and all sessions were video recorded. Cats ate more food from the free feed tray than the puzzle (t (16) = 6.77, p < 0.001). Cats made more first choices to approach and eat from the tray. There was no relationship between activity and contrafreeloading, and there was no effect of sex, age, or previous food puzzle experience on contrafreeloading. Our results suggest that cats do not show strong tendencies to contrafreeload in the home environment, although some cats (N = 4) ate most food offered in the puzzle or showed weak contrafreeloading tendencies (N = 5). Eight cats did not contrafreeload. Cats who consumed more food from the puzzle, consumed more food in general, suggesting a relationship between hunger and effort. Further research is required to understand why domestic cats, unlike other tested species, do not show a strong preference to work for food.
Subject(s)
Food , Animals , CatsABSTRACT
SARS-CoV-2 has currently precipitated the COVID-19 global health crisis. We developed a medium-throughput drug-screening system and identified a small-molecule library of 34 of 430 protein kinase inhibitors that were capable of inhibiting the SARS-CoV-2 cytopathic effect in human epithelial cells. These drug inhibitors are in various stages of clinical trials. We detected key proteins involved in cellular signaling pathways mTOR-PI3K-AKT, ABL-BCR/MAPK, and DNA-damage response that are critical for SARS-CoV-2 infection. A drug-protein interaction-based secondary screen confirmed compounds, such as the ATR kinase inhibitor berzosertib and torin2 with anti-SARS-CoV-2 activity. Berzosertib exhibited potent antiviral activity against SARS-CoV-2 in multiple cell types and blocked replication at the post-entry step. Berzosertib inhibited replication of SARS-CoV-1 and the Middle East respiratory syndrome coronavirus (MERS-CoV) as well. Our study highlights key promising kinase inhibitors to constrain coronavirus replication as a host-directed therapy in the treatment of COVID-19 and beyond as well as provides an important mechanism of host-pathogen interactions.
